Edwards Lifesciences Corp. said Thursday it authorized a new $1 billion stock repurchase program. At Wednesday’s stock closing price of $113.36, the program could represent about 4.2% of the shares outstanding. Separately, the heart disease treatment company said it entered into a $150 million accelerated stock buyback deal in November. The company also affirmed its 2017 financial guidance, and projected 2018 adjusted earnings per share of $4.10 to $4.30, compared with the FactSet consensus of $4.14. Revenue is expected to be $3.5 billion to $3.9 billion in 2018, representing underlying growth of 9% to 10%, and surrounding the FactSet consensus of $3.7 billion. “Our global growth is being driven by our transcatheter aortic valve therapies, and continued advancement in each of our market-leading product lines,” said Chief Executive Michael A. Mussallem. The stock, which was still inactive in premarket trade, has rallied 21% year to date, while the SPDR Health Care Select Sector ETF has climbed 19% and the S&P 500 has gained 17%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Latest posts by Market Watch (see all)
- The Wall Street Journal: Trump says he has ‘no reason’ to listen to tape of Khashoggi’s death - November 18, 2018
- The Wall Street Journal: Trump says he’s dissatisfied with Kristjen Nielsen, open to John Kelly moving on - November 18, 2018
- Key Words: Apple’s Tim Cook says tech regulation ‘inevitable’ because free market isn’t working - November 18, 2018